Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: a randomized study

Asselah T, Pol S, Hezode C, et al. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: a randomized study. Liver Int. 2020;40(5):1042-1051.

Publication Type:

Journal Article

Authors:

Asselah, T; Pol, S; Hezode, C; et, al

Source:

Liver Int, Volume 40, Issue 5, p.1042-1051 (2020)

Cited On:

Export Citation:
RIS Format
Top